Children born profoundly deaf have begun to hear for the first time after a single dose of gene therapy, in what doctors describe as a landmark for the field. The treatment, DB-OTO, was approved by the US Food and Drug Administration in April 2026 under the name Otarmeni, becoming the first gene therapy ever approved for congenital hearing loss. In the CHORD trial, 12 children with profound deafness caused by mutations in the OTOF gene received one infusion of the therapy directly into the inner ear. Hearing improved in 11 of the 12 children, nine reached a level that ended their need for a cochlear implant, and three achieved normal hearing sensitivity within six months. A separate international trial led by Mass Eye and Ear and Fudan University, published in Nature in April 2026, treated 42 people aged from under a year to 32 years and found hearing improved in about 90 percent, with benefits lasting up to two and a half years.
What the Evidence Shows
The therapy works by delivering a working copy of the OTOF gene into the inner ear using a harmless virus, restoring production of otoferlin, a protein that inner hair cells need to pass sound signals to the brain. The condition it treats, known as DFNB9, accounts for roughly 2 to 8 percent of hereditary cases of congenital sensorineural hearing loss and affects about 50 babies born each year in the United States. Cochlear implants, the current treatment, bypass the hair cells entirely, so they manage the symptoms without restoring natural hearing. Younger children and those with healthier inner ears responded best, and children treated in both ears scored higher on language and speech tests. About one in ten participants did not respond, and researchers are following patients to confirm the benefit lasts for life. Reporting and analysis from sources such as World Health Organization track the same developments, and specialists following gene therapy for inherited deafness say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around gene therapy for inherited deafness is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for gene therapy for inherited deafness depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.
